NCT02189603View on ClinicalTrials.gov

Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）

PHASE4CompletedINTERVENTIONAL
Enrollment

601

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 7, 2015

Study Completion Date

December 7, 2015

Conditions
Hepatitis E
Interventions
BIOLOGICAL

Recombinant (E. Coli) Hepatitis E Vaccine

Trial Locations (1)

361000

Center for disease control and prevention in Xiamen haicang district, Xiamen

All Listed Sponsors
collaborator

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

collaborator

Xiamen Center for Disease Control and Prevention

UNKNOWN

lead

Jun Zhang

OTHER

NCT02189603 - Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®） | Biotech Hunter | Biotech Hunter